TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference
January 15 2021 - 7:00AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael
S. Weiss, the Company’s Executive Chairman and Chief Executive
Officer, will participate in a fireside chat during the B. Riley
Securities Oncology Investor Conference being held virtually. The
fireside chat is scheduled to take place on Wednesday, January 20,
2021 at 10:00 AM ET.
A live webcast of this presentation will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events. A
replay of the webcast will be available on TG’s website following
the event.
ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. Currently, the company is developing
multiple therapies targeting hematological malignancies and
autoimmune diseases. Ublituximab (TG-1101) is a novel,
glycoengineered monoclonal antibody that targets a specific and
unique epitope on the CD20 antigen found on mature B-lymphocytes.
TG Therapeutics is also developing umbralisib (TGR-1202), an oral,
once-daily dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib
is currently under review by the U.S. Food and Drug Administration
(FDA) for accelerated approval as a treatment for patients with
previously treated marginal zone lymphoma (MZL) who have received
at least one prior anti-CD20 based regimen or follicular lymphoma
(FL) who have received at least two prior systemic therapies. Both
ublituximab and umbralisib, or the combination of which is referred
to as "U2", are in Phase 3 clinical development for patients with
hematologic malignancies, with ublituximab also in Phase 3 clinical
development for Multiple Sclerosis. Additionally, the Company has
recently brought into Phase 1 clinical development its anti-PD-L1
monoclonal antibody, cosibelimab (TG-1501), its Bruton’s Tyrosine
Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19
bispecific antibody, TG-1801. TG Therapeutics is headquartered in
New York City.CONTACT:
Jenna BoscoSenior Vice President, Corporate CommunicationsTG
Therapeutics, Inc.Telephone: 212.554.4351Email: ir@tgtxinc.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024